| Similar Articles |
|---|
 |
The Motley Fool
April 16, 2008
Brian Lawler |
Cephalon Convinces the Continent The pharmaceutical's lead pain drug gets approved for marketing in Europe.   |
The Motley Fool
July 6, 2006
Brian Lawler |
Cephalon on the Hunt The biopharma company is looking to make more acquisitions and gets some good news from the FDA. Cephalon's stock climbed by more than 10% after the announcement. |
The Motley Fool
September 14, 2007
Brian Lawler |
"Dear Doctor" Letter Spells Trouble for Cephalon Cephalon sends a letter to health-care practitioners warning of the dangers of misusing one of its lead drugs, Fentora. Investors, take note. |
The Motley Fool
May 7, 2008
Brian Lawler |
Cephalon's Long Shot Falls Short An FDA advisory panel brings bad news for the company. |
The Motley Fool
November 6, 2006
Brian Lawler |
No Worries About Cephalon This solid biopharma ups its yearly guidance -- for the fourth time. Investors, take note. |
The Motley Fool
November 22, 2006
Brian Lawler |
How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line. |
The Motley Fool
November 4, 2004
Charly Travers |
Drug Growth Screeching to a Halt Given the threat of generics to not-so-small drug company Cephalon's product line, the acquisition of CIMA labs in August of this year could turn out to be quite important. |
The Motley Fool
February 16, 2007
Brian Lawler |
Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note. |
The Motley Fool
April 27, 2007
Brian Lawler |
Cephalon's Earnings Surprise The drugmaker raises its earnings guidance for the year. With no serious competition for its lead compounds in the near term, investors should take a look at the well-run pharma. |
The Motley Fool
September 27, 2007
Brian Lawler |
FDA Repeats Itself With Cephalon's Fentora In the wake of a letter from Cephalon to health-care practitioners, the FDA has issued a press release and a public health advisory of the dangers of misusing the company's pain drug Fentora. Investors, take note. |
The Motley Fool
June 27, 2006
Brian Lawler |
Cephalon Stays Busy The announcement of Gabitril's phase 3 failure was definitely not good news for Cephalon. However, if the market panics and drives the stock down, investors could find themselves with a great buying opportunity. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
April 2, 2007
Brian Lawler |
FDA Keeps Cephalon Waiting The FDA issues Cephalon an approvable letter for one of its drugs. Investors, take note. |
The Motley Fool
February 14, 2008
Brian Lawler |
Waking Cephalon Up Specialty pharma Cephalon presents its 2007 financial results and 2008 guidance. |
The Motley Fool
March 24, 2006
Brian Gorman |
Cephalon Takes a Hit The FDA rules against its ADHD drug, but Cephalon's current lineup still holds promise. Investors may want to look at the current sell-off as a potential buying opportunity. |
The Motley Fool
August 27, 2007
Brian Lawler |
Cephalon Makes A Deal The newest drug in its cabinet is expected to hit the U.S. market in the fourth quarter. Investors will know relatively soon whether Cephalon pulled off another coup or just flushed $100 million down the toilet. |
The Motley Fool
August 13, 2004
Rich Duprey |
Cima's Breakup Mess The pharmaceutical company seeks to recoup its fees plus damages from a former suitor. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
October 16, 2006
Brian Lawler |
The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note. |
The Motley Fool
September 4, 2008
Brian Lawler |
Sitting Tight in September This month, several drugmakers will hear about compounds awaiting approval, so we can expect some volatility in their share prices. Read on to see who's awaiting FDA news. |
The Motley Fool
November 9, 2007
Brian Lawler |
Cephalon Wheels and Deals Sales and net income fall in the third quarter, but increased guidance sends shares of the drugmaker higher. |
The Motley Fool
August 19, 2004
Charly Travers |
1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
BusinessWeek
June 24, 2010
Bliss & Decker |
Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
February 17, 2006
Brian Gorman |
Enthusiasm for Cephalon The company seems to be counting on a strong showing for a new drug, but for investors, it may pay to be cautious. |
The Motley Fool
February 7, 2006
Stephen D. Simpson |
Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future. |
The Motley Fool
November 8, 2006
Brian Lawler |
Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note. |
The Motley Fool
March 30, 2005
David Nierengarten |
Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives? |
BusinessWeek
December 11, 2006
Michael Arndt |
Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West. |
The Motley Fool
March 30, 2010
Brian Orelli |
FDA Lags, Investors Flee Cephalon gets no love from the FDA. The agency failed to expand Cephalon's Nuvigil for the treatment of jet lag. |
The Motley Fool
August 3, 2007
Brian Lawler |
Cephalon's Case of Spending Blues Cephalon announces its second-quarter financial results. Sales were up, so why is the share price down? Perhaps escalating SG&A expenses are the culprit. |
The Motley Fool
June 27, 2005
Brian Gorman |
Alkermes' Powerful Partnership Alkermes recently agreed to partner with Cephalon to commercialize Alkermes' Vivitrex, an experimental drug to treat alcoholism. The deal should bring strong sales and valuable experience. |
The Motley Fool
May 2, 2007 |
Strong Sales at Cephalon: Fool by Numbers The pharmaceutical released earnings for its fiscal first-quarter 2007: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
BusinessWeek
April 24, 2006
Arlene Weintraub |
Eyes Wide Open Cephalon's careful marketing of its narcolepsy drug could serve as a manual for turning new ideas into hit products. |
BusinessWeek
November 1, 2004
Amy Barrett |
This Pep Pill is Pushing Its Luck Half of Provigil prescriptions may be for "off-label" uses. Did its maker cross the line? But Cephalon is hardly the only drugmaker in the spotlight. |
The Motley Fool
December 29, 2006
Brian Lawler |
No Pain for Alexza December's been good to lots of pharmas, but Alexza in particular has something to thank Santa for. Investors should pay close attention when Alexza issues its AZ-001 trial results next year. |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
The Motley Fool
December 31, 2007
Brian Lawler |
Cephalon's Date With the FDA In the last day of the year, Cephalon announces that it has submitted another New Drug Application for oncology treatment Treanda. Expect to hear back from FDA on this priority review before the middle of 2008. |
The Motley Fool
March 30, 2011
Brian Orelli |
Valeant Vultures Will Cephalon manage to rebuff Valeant's advances? |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
The Motley Fool
November 3, 2006 |
Cephalon Soars: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 1, 2008
Brian Lawler |
Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
Chemistry World
May 4, 2011
Andrew Turley |
Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant. |
The Motley Fool
May 2, 2011
Arundhati Parmar |
Teva pays $6.8B to buy Cephalon, including Minnesota's CIMA Labs Teva diversifies. |
Pharmaceutical Executive
March 1, 2007
Walter Armstrong |
He's Just Being Frank Cephalon's Frank Baldino is going global with plans to corner cancer. |
